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Mohiuddin et al General Thoracic Surgeryresection, multifocal disease, induction therapy, distant me-
tastases, large cell cancer, and adenosquamous cancer were
all excluded. Although this limited the generalizability of
these results, it has enhanced the validity by reducing the
heterogeneity in the study population.G
T
SCONCLUSIONS
The focus of the present study was on the distance from
the primary tumor to the closest margin in wedge resection.
Crucially, we could not report on the differential effect that
the margin distance might have for tumors of different sizes
because we did not have enough power to detect the effect.
However, we did not restrict the results to a specific postu-
lated margin-to-tumor size ratio but, rather, quantified the
effect of the margin distance, in general, on the risk of recur-
rence. We found that an increasing margin distance yielded
decreased local recurrence rates for a margin distance of
15 mm, regardless of the tumor size when the tumors
were 2 cm. Thus, we can decrease the risk of local recur-
rence during wedge resection of small NSCLC if we can
achieve an adequate (15 mm) margin distance. Although
we believe our results speak to the potential benefits associ-
ated with a resection margin of 15 mm, they cannot
specify the ideal margin distance for small tumor size. Our
results suggest that an important avenue for future work
will be to gather more data from patients from other insti-
tutes and to further determine the optimal margin distance
for small tumors. This association should be investigated
in future studies that explicitly consider the relationship be-
tween the margin distance and local recurrence.References
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Dr Joshua R. Sonett (New York, NY). Thank you for your
excellent presentation and for the rather significant effort and en-
ergy to collect, analyze, and study this large cohort of patients.
Having pathologic data with long-term follow-up of patients
who underwent wedge resection for this is important, because
our treatment options for early-stage lung cancer are continually
debated, not only by surgeons. As our less invasive options for
treating lung cancer are introduced, we need to ensure we do not
diminish our cure rates at the heels of ease, expediency, and
minimalism.
Your results build on the results from El-Sherif in that 1-cm
margins are important, and you conclude that>1.5 cm might be
the point of diminishing return. I, similar to probably half this audi-
ence, do not understand spline statistics, but I had a very competent
statistician look at it for me. They thought your data were donediovascular Surgery c Volume 147, Number 4 1175
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Svery well in terms of the statistics, although the>1.5-cm popula-
tion was a little bit low in the number of patients you had, those
with margins>1.5 cm.
I have several questions, more about the philosophy for wedge
resection and how you responded to the results. By the age of your
patients when I read your report, the pulmonary function, which
was pretty reasonable in a large population, and the tumor location,
which was predominantly right upper lobe, left upper lobe, and
middle lobe, it appears to me that these patients would have easily
tolerated much larger resections. So, how do you presently decide,
short of the currently randomized Cancer and Leukemia Group B
(CALGB) trial, in which patients with<2-cm tumors receive a
wedge resection?
Dr Mohiuddin. Thank you very much.
We presently decide according to patient age, tumor size, tumor
location, percentage of forced expiratory volume in 1 second
(FEV1), distant metastasis, and patient comorbidities. Those are
our criteria.
Dr Sonett. In your data, 60% of your patients had<1-cm mar-
gins and 67% had no lymph nodes sampled. Again, this was by
very competent thoracic surgeons. So, what is your current prac-
tice for lymph node sampling in these patients? Do you think it
is relevant in this cohort to sample the lymph nodes, and how
can you advocate for surgical resection instead of, say, stereotactic
body radiotherapy (SBRT) if we are not going to sample the nodes
and achieve>1-cm margins?
Dr Mohiuddin. Our current practice is to take the lymph nodes,
and we strongly think it is relevant to sample the lymph nodes. How
weadvocate surgical resection overSBRT,webelieve surgical resec-
tion has more advantages and benefits, such as sampling the lymph
nodes. With SBRT, we cannot sample the lymph nodes. No long-
term data are yet available on the effect of radiation on the lungs.
Dr Sonett. Much of the published data, and I would say
including the last report and Dr Faber’s discussion, have shown
improved results with segmental resection. Now, it is not clear
whether the benefit of segmental resection results from actually
removing the anatomic segment and lymphatics versus just attain-
ing a good, safe margin. Given your data presented, do you mea-
sure the distance of your margin in the operating room and
consider performing either a larger resection or segmentectomy
if the margin is not adequate as you had defined?
Dr Mohiuddin. We ensure that the surgical resection margin is
negative in the operating room, and we do measure the distance,
and we do consider performing a larger resection or a segmentec-
tomyor lobectomy if the patient has an adequate percentage of FEV1.
DrSonett.So, as opposed to the historical data, now that youhave
shown these data, if youwere to performawedge resection right now
with a<1-cm margin, what would be your course of events?
Dr Mohiuddin. Sorry, can you repeat the question?
Dr Sonett. If you were to perform a wedge tomorrow for a
lesion and, pathologically, on frozen section analysis, the margin
was<1 cm, what would be your answer in the operating room?
Dr Mohiuddin.We have 2 options. It all depends on the FEV1
for determining whether we can go back and resect at the same
time.
Dr Scott J. Swanson (Boston, Mass). I can maybe answer that.
Kamran is a fellow, and I think he is not going to really make that
decision. I think our philosophy based on the learning from this1176 The Journal of Thoracic and Cardiovascular Surdatabasewould be to perform amore aggressive resection, whether
segmentectomy or lobectomy, with nodal dissection, and I think
this has been pretty informative for us. The points you brought
up are pretty revealing. So, we are taking this forward to do a
more aggressive resection. But, is 15 mm the right number? I do
not think we know that. However, if we believe that we are not
at least over the tumor diameter ratio, I think most of us would
do a larger resection.
Dr Sonett. Well, if you consider Dr Altorki’s results, you
consider your results, and you consider the prospective trial on ra-
diation seeds that was presented at the Southern, those 3 trials, all
by really good, dedicated thoracic surgeons, all hadmiserable mar-
gins. So it would be hard for us to advocate for surgery when we
are achieving crappy margins against SBRT. I think we as a group
have to either do better segmental resections or perform lobec-
tomies, but we cannot perform a crappy wedge resection with
small margins just to try to keep pace with SBRT, because we
will not be doing anybody a favor, including ourselves and our
patients.
Dr Harvey Pass (New York, NY). I would like to follow-up on
what Josh said and also to ask the Brigham group. The Brigham
group is known, not only for terrific thoracic surgery, but also for
terrific radiology imaging. My problem as an old surgeon is where
is the lesion? There are easy wedges, and there are deep wedges
that are not very easy. You have a study that considered themargins
and you also have imaging studies for all these patients. Is not this
the perfect study to also correlate the image findings preoperatively
of where the lesion is andwhether you could actually document be-
forehand whether you could perform an adequate resection? The
deeper lesions will be the ones that, yes, you find you cannot resect
and achieve a 1-cm margin, but you cannot do another resection;
you must use segmentectomy. As I get older, I like to plan and
know what I will have to do beforehand. I think that your imaging
data at the cross-sectional diameter, where this is, and the distance
from the hilum as a uniform point, or from the visceral pleura,
could be very enlightening regarding whether you approach a
case as a wedge or segmentectomy.
Dr Mohiuddin. I agree with you. Thanks.
Dr Daniel L. Miller (Atlanta, Ga). We are killing ourselves
here. I mean from the point of view of lymph node evaluation,
we suck: 67%, nothing in this. The previous study, 44%. We are
giving these cases away. That is not acceptable. I am sorry; it is
not. Wemust do a better job at that or we are going to lose this busi-
ness. SBRT results in a 5-mmmargin.We are coming down to their
level. We must do better than that. Now, I think it is embarrassing
that we have these studies that show that. If the values are not there,
we take that out of our analysis. But we must do a better job or we
are going to lose this.
My 1 question I have is, did you consider the biohistologic fea-
tures of the tumor? Was there a difference in the lymphatic inva-
sion, neuroinvasion, and vascular invasion and was there a
difference in visceral pleural invasion? I think that considers recur-
rence and so forth, but we must do better.
DrMohiuddin. I agree with you. We did include lymphovascu-
lar invasion and pleural invasion, and we adjusted for that in our
analysis.
DrMiller. But, did you have to resect a larger volume for those
patients?gery c April 2014
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SDrMohiuddin. I agree. We need more patient data. Right now,
we cannot comment on that.
Dr Michael I. Ebright (Boston, Mass). I am going to follow-up
on Dr Pass’s point. Previous studies have suggested that tumors
within the central one third of the lung, the central tumors, will
have up to a 50% rate of lymph node metastases. As one’s tumors
become more central, it becomes more technically difficult or
perhaps not even feasible to perform a sublobar resection with a
wedge, and we might need to default to segmentectomy, even if
that would not be our initial preferred approach. I would assume
that most of the tumors in your studies were peripheral, but I am
wondering whether you have any data to suggest whether you are
treating the peripheral tumors differently than the central tumors.
Dr Mohiuddin. I agree. In our data we have had more periph-
eral tumors. That was determined by the radiologic evaluation.
The radiologist evaluated within the hemithorax the location,
and from our data, you are right.
Dr David C. Rice (Houston, Tex). How did you measure your
margin? The Sawabata report measured it from the cut edge of
the staple line and did smears on that; thus, that little 5-mm bit
was included in their margin.
I also want to make a comment. We are shooting ourselves in the
foot if we continue to call this local recurrence, because the radiationThe Journal of Thoracic and Caroncologists, like it or not, are not going to playbyour rules.Theyhave
termed recurrence at the tumor site ‘‘local recurrence.’’ This is really
locoregional recurrence if you are including the lymph nodes. I
would beg you to include that in your report, at least make it clear,
so that an internist will at least be able to compare appleswith apples.
Dr Mohiuddin. The resection margin was evaluated by the
pathologist, and it was the distance from the tumor to the resection
margin, not including the staple line.
I am sorry, can you repeat the second question?
Dr Rice. That is okay. It was just a comment.
Dr Gunda Leschber (Berlin, Germany). I would like to come
back to this margin and the measurement of the margin. You said
the pathologist measured it, but was it with an inflated lung or was
it in a formalin-fixed lung? When was it measured? We know that
the margin will shrink if we put it in formalin.
Dr Mohiuddin. It was in an inflated lung.
Dr Thomas Rice (Cleveland, Ohio). I am curious about your
need to create a new term. ‘‘Margin length.’’ I expected you to
measure the length of the margin. Why did you not call it what
we all call it—the distance from the primary tumor to the closest
margin. Be precise. Be accurate. You are a surgeon. I would
change your term ‘‘margin length.’’
Dr Mohiuddin. Thank you.diovascular Surgery c Volume 147, Number 4 1177
